# David R. Gandara

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-r-gandara/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,305 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 100 |
| i10-index | 467 |
| Last Known Institution | Comprehensive Blood & Cancer Center |
| OpenAlex ID | https://openalex.org/A5036091074 |
| ORCID iD | https://orcid.org/0000-0003-1784-048X |
| Works | 1,110 |

## Researcher papers

- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-comparing-cisplatin-plus-gemcitabine-with-cisplatin-plus/)
- [Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer](https://scholariq.org/papers/vinorelbine-plus-cisplatin-vs-observation-in-resected-non-small-cell-lung-cancer/)
- [Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial](https://scholariq.org/papers/radiotherapy-plus-chemotherapy-with-or-without-surgical-resection-for-stage-iii/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC](https://scholariq.org/papers/liquid-biopsy-for-advanced-non-small-cell-lung-cancer-nsclc-a-statement-paper/)
- [Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer](https://scholariq.org/papers/liquid-biopsy-for-advanced-nsclc-a-consensus-statement-from-the-international/)
- [Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study](https://scholariq.org/papers/gefitinib-versus-placebo-in-completely-resected-non-small-cell-lung-cancer/)
- [Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry](https://scholariq.org/papers/targeting-ret-in-patients-with-i-ret-i-rearranged-lung-cancers-results-from-the/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Comprehensive Blood & Cancer Center](https://scholariq.org/institutions/comprehensive-blood-and-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.